|Positron Sees Tenfold Increase in Quote Proposals|
|By Staff and Wire Reports|
|Saturday, 22 May 2010 14:22|
Shares of Positron Corporation (OTCBB:POSC), the molecular imaging solutions company focused on Nuclear Cardiology, rose nearly 16% after they stated that over the first 4 months of 2010 that it has seen tremendous interest in their Attrius™ dedicated cardiac PET scanner. The Attrius™ was introduced in the 4th quarter of 2009 and has been met with critical acclaim throughout the molecular imaging industry.
Patrick G. Rooney, Positron Corporation’s CEO states, “The Nuclear Cardiology industry is experiencing a shift from SPECT to PET as a result of molly shortages combined with changes in reimbursement. Positron is in an ideal position to capitalize on this shift more so than any other imaging company. The Attrius™ is a state of the art, Frost & Sullivan New Product Innovation Award winning, device that was designed to be optimized for Cardiac imaging allowing physicians an easy transition to PET. Our pipeline for PET systems has had significant increases each month since we launched the Attrius™ late last year.
Our current pipeline has over 55 potential and/or pending sales with the second half on the year still too follow. We have done a very good job of positioning Positron to meet this new demand. Based on the current interest we believe we will meet or exceed our projected system sales moving forward. Positron’s objective is to be the leader in cardiac PET solutions. We believe we will continue to see substantial growth from both devices and radiopharmaceuticals."